Online skin self-exam program for melanoma survivors
A Digital Intervention to Improve Skin Self-examination Among Melanoma Survivors
This study is testing a new online program to help melanoma survivors do better skin self-exams and see if it works better than just reading an educational webpage.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 385 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Rutgers, The State University of New Jersey Academic / other |
| Locations | 1 site (New Brunswick, New Jersey) |
| Trial ID | NCT05373823 on ClinicalTrials.gov |
What this trial studies
This project, mySmartSkin, is designed to improve skin self-examination practices among melanoma survivors through a hybrid effectiveness-implementation approach. It involves enhancing the existing mySmartSkin program by collaborating with stakeholders to gather insights and conduct usability testing. The study will then evaluate the effectiveness of this enhanced program in a randomized control trial, comparing it to an educational webpage, while also assessing implementation outcomes to facilitate future dissemination. The trial aims to engage multiple stakeholders and identify factors critical for scaling up the intervention in community and healthcare settings.
Who should consider this trial
Good fit: Ideal candidates are melanoma survivors aged 18 and older, who are 3 to 5 years post-surgery, have no current evidence of cancer, and are not adherent to thorough skin self-examinations.
Not a fit: Patients who are currently undergoing treatment for melanoma or have evidence of active cancer may not benefit from this study.
Why it matters
Potential benefit: If successful, this program could significantly improve early detection of new or recurrent melanomas among survivors.
How similar studies have performed: Other studies have shown promise in enhancing self-examination practices among cancer survivors, indicating that this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of primary pathologic stage 0-III cutaneous malignant melanoma * Three months to five years post-surgery * No current evidence of cancer * Not adherent to thorough SSE (i.e., did not check entire body at least once during the past three months) * ≥ 18 years old * Internet access * Able to speak/read English * Able to provide informed consent Exclusion Criteria: * Children
Where this trial is running
New Brunswick, New Jersey
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey, United States (Recruiting)
Study contacts
- Principal investigator: Sharon Manne, PhD — Rutgers Cancer Institute of New Jersey
- Study coordinator: Sharon Manne, PhD
- Email: mannesl@cinj.rutgers.edu
- Phone: 732-235-6759
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.